Supportive Medicines Phase 5a - Propofol 1g/50ml Emulsion for Infusion

Concepts

• pharmaceutical products
• propofol 1g
• supportive medicines
• 50ml emulsion
• vials of propofol 1g
• infusion
• ml emulsion
• social care
• department of health
• department of health and social care

Location

United Kingdom: Haydock, England

Description

A requirement for the supply of 375,000 vials of Propofol 1g / 50 ml emulsion for infusion (for use in Intensive Treatment Units) in preparation for further waves of Covid 19 in Winter 2021/Spring 2022.

Total Quantity or Scope

The Department of Health and Social Care (DHSC) has awarded a contract for the supply of 375,000 vials of Propofol 1g / 50 ml emulsion for infusion (for use in Intensive Treatment Units) in preparation for further waves of Covid 19 in Winter 2021/Spring 2022. The contract was awarded on behalf of United Kingdom Health Security Agency (UKHSA)

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Legal Justification

The Coronavirus disease (Covid-19) is a serious infectious respiratory disease and its consequences pose a risk to life. The Covid-19 pandemic supportive medicines stockpile was designed as a ‘one off’ build to target volumes of a defined range of critical products used within the intensive treatment units and end of life environments. However, developments in Winter 2021 around the Omicron variant and heightened risk perception within Government prompted activation of the ‘Challenging Winter Peak’ Scenario at very short notice, resulting in an urgent requirement to procure additional volumes of some critical products to avoid their complete stockout in the month of January 2022. The global stock of Propofol is limited and there are many buyers competing for the same supplies. It is imperative that security of supply is maintained for public health purposes. Due to the short delivery timeframe required to mitigate a complete stockout, the authority did not have sufficient time to comply with the standard open procedure time scales for this procurement. Accordingly, the Authority used the negotiated procedure without prior publication – Regulation 32(2)(c) – Extreme Urgency Route (i.e. direct award) permitted under the Public Contract Regulations 2015 (as amended) to conduct this procurement

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per vial. This will (i) commercially prejudice the contracting authority in its commercial dealings with other suppliers; and (ii) impact fair competition between suppliers.The Contract is for the benefit of the Authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of Products to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting Products delivered against the contract may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories .